Quince Therapeutics, Inc.

QNCX

Quince Therapeutics, Inc.

QNCX

Insider Sentiment (TTM):

Last Purchase:2024-08-30Last Sale:2025-12-26Shares Purchased (TTM):0Shares Sold (TTM):50,000

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:12,624,794Shares Outstanding:9,120,267Institutional Ownership Pct.:138.43%

Earnings Market Reaction:

Filing Date:2026-08-14Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	116	18	6	6	17	8	6	3	8	22	21	22
Available For Sale Securities Debt Securities Curr…	-	-	-	-	-	-	35	45	52	46	54	62
Debt Securities Available For Sale Excluding Accru…	-	-	12	20	18	24	35	-	-	-	-	-
Short Term Investments	0	0	-	-	-	-	-	-	-	-	-	-
Prepaid Expense And Other Assets Current	7	7	5	3	3	2	3	4	4	3	2	1
Assets Current	123	26	23	29	37	34	44	52	63	70	77	85
Property Plant And Equipment Net	1	1	1	1	1	0	0	0	0	0	0	0
Operating Lease Right Of Use Asset	0	0	0	0	1	0	0	1	1	0	0	0
Goodwill	-	-	-	-	-	-	0	0	0	17	18	-
Intangible Assets Net Excluding Goodwill	0	0	68	68	68	62	60	65	62	62	64	0
Available For Sale Securities Debt Securities Nonc…	-	-	-	-	-	-	-	-	-	-	0	0
Other Assets Noncurrent	0	0	2	12	11	10	10	10	9	8	9	-
Assets	124	27	94	110	117	107	114	127	135	159	168	85
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	5	5	2	3	2	3	3	2	2	2	2	0
Accrued Liabilities Current	4	3	11	5	6	5	4	4	3	3	3	2
Long Term Debt Current	0	0	18	18	-	-	0	-	-	-	-	-
Business Combination Contingent Consideration Liab…	0	0	12	-	-	-	0	0	5	5	4	-
Liabilities Current	9	9	43	26	7	8	7	5	10	10	10	2
Long Term Debt	-	-	0	0	17	15	14	15	14	14	13	-
Operating Lease Liability Noncurrent	0	0	0	0	0	0	0	0	0	0	0	-
Business Combination Contingent Consideration Liab…	0	0	52	61	59	59	57	55	57	56	54	-
Deferred Income Tax Liabilities Net	-	-	0	6	6	5	5	5	5	5	5	0
Other Liabilities Noncurrent	1	1	2	1	1	1	1	1	1	1	1	-
Liabilities	16	11	129	109	105	89	84	82	88	85	83	2
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	460	436	419	416	413	408	407	405	404	403	402	393
Accumulated Other Comprehensive Income Loss Net Of…	4	5	6	6	6	2	-0	3	1	2	3	1
Retained Earnings Accumulated Deficit	-500	-425	-460	-421	-408	-392	-376	-364	-359	-331	-320	-311
Stockholders Equity	-35	16	-36	1	12	19	30	45	47	74	85	83
Liabilities And Stockholders Equity	124	27	94	110	117	107	114	127	135	159	168	85
Series A Preferred Stock	-	-	-	-	-	-	-	0	0	0	0	-
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	250	250	250	250	250	100	250	100	100	100	100	100
Common Stock Shares Issued	1	14	56	54	0	0	44	0	0	0	0	0
Shares Outstanding	1	14	56	54	0	0	44	0	0	0	0	0

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-18.55%	-30.52%	-7.14%	-	-	-	-	-	-	-	-	-
2025	23.16%	69.47%	76.84%	0.62%	3.12%	3.12%	134.50%	75.44%	-90.06%	-2.21%	-15.44%	-30.59%
2024	-14.13%	-20.76%	-23.91%	21.18%	36.98%	167.36%	32.08%	22.64%	1.26%	-29.21%	-39.29%	2.14%
2023	-	-	-	-	-	-	7.58%	28.21%	48.27%	-2.75%	-22.02%	-35.78%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	14.52	2.92	0.53	1.12	5.00	4.05	6.05	9.53	6.15	7.16	8.09	37.80
Quick Ratio	13.64	2.07	0.41	1.01	4.65	3.78	5.60	8.82	5.76	6.89	7.84	37.16
Working Capital	114.91M	16.81M	-20.33M	3.16M	29.88M	25.47M	36.76M	46.29M	53.12M	60.60M	67.87M	82.92M
Leverage & Debt
Debt to Equity	-0.44	0.70	-3.62	102.78	8.99	4.76	2.80	1.82	1.87	1.15	0.97	0.03
Debt Ratio	0.13	0.41	1.38	0.99	0.90	0.83	0.74	0.64	0.65	0.53	0.49	0.03
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-15.08	-3.59	-1.68	-1.06	-210.04	-13.82	-1.31	-1.23	-246.53	-140.80	-168.57	-155.38
Free Cash Flow Per Share TTM	-8.01	-4.35	-0.83	-0.54	-113.85	-7.63	-0.74	-0.71	-130.36	-107.60	-99.11	-101.26
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	88.61%	-45.58%	47.78%	6.97%	-7.71%	100.49%	81.07%	90.06%	73.63%	-28.37%	-39.25%	-59.69%
EPS Growth (1Y)	-92.82%	-73.78%	27.62%	-14.41%	-14.80%	-90.19%	-99.22%	-99.21%	44.71%	-40.29%	-45.35%	-60.21%
Valuation Metrics
P/E TTM	-1.21	-5.58	-399.68	-308.68	-1.57	-19.25	-284.72	-125.77	-0.61	-1.51	-1.25	-1.44
P/B TTM	-3.16	11.76	-939.83	16,608.26	6.56	62.90	536.72	149.09	0.69	0.61	0.46	0.49
Market Cap	111.56M	184.23M	33.56B	17.59B	77.03M	1.17B	16.18B	6.70B	32.32M	45.59M	39.10M	40.40M
Enterprise Value	-4.42M	166.07M	33.58B	17.60B	77.20M	1.18B	16.19B	6.71B	38.27M	37.30M	31.78M	18.77M
Calculated Values
Free Cash Flow TTM	-49.12M	-39.70M	-41.82M	-29.27M	-26.58M	-33.52M	-32.16M	-30.58M	-28.09M	-23.14M	-18.45M	-18.26M
Net Debt	-115.98M	-18.16M	12.22M	11.07M	163.00K	7.50M	8.11M	12.22M	5.94M	-8.30M	-7.32M	-21.63M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-12-26Sale

Owner: Benatti, Luca

Title: -

Shares: 50,000

Price/Share: $3.47

Value: $173,500.00

Shares Owned: 39,179

Relationship: Director

Ownership: Direct

2024-08-30Purchase

Owner: Thye, Dirk

Title: CEO AND CHIEF MEDICAL OFFICER

Shares: 77,000

Price/Share: $0.70

Value: $53,900.00

Shares Owned: 843,941

Relationship: Director,Officer

Ownership: Direct

2024-08-21Purchase

Owner: Hannah, Brendan

Title: CHIEF BUSINESS OFFICER AND COO

Shares: 30,845

Price/Share: $0.62

Value: $19,123.90

Shares Owned: 296,540

Relationship: Officer

Ownership: Direct

2024-08-20Purchase

Owner: Ryan, Charles S.

Title: PRESIDENT

Shares: 48,387

Price/Share: $0.65

Value: $31,451.55

Shares Owned: 122,461

Relationship: Officer

Ownership: Direct

2023-12-14Purchase

Owner: Lamond, David

Title: -

Shares: 22,627

Price/Share: $1.04

Value: $23,532.08

Shares Owned: 2,347,545

Relationship: Director

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-12-26	Benatti, Luca	Director	-	Direct	Sale	50,000	3.47	$173,500.00	39,179	4
2024-08-30	Thye, Dirk	Director,Officer	CEO AND CHIEF MEDICAL OFFICER	Direct	Purchase	77,000	0.70	$53,900.00	843,941	4
2024-08-21	Hannah, Brendan	Officer	CHIEF BUSINESS OFFICER AND COO	Direct	Purchase	30,845	0.62	$19,123.90	296,540	4
2024-08-20	Ryan, Charles S.	Officer	PRESIDENT	Direct	Purchase	48,387	0.65	$31,451.55	122,461	4
2023-12-14	Lamond, David	Director	-	Indirect	Purchase	22,627	1.04	$23,532.08	2,347,545	4
2023-12-07	Lamond, David	Director	-	Indirect	Purchase	19,123	1.01	$19,314.23	2,279,664	4
2023-12-01	Lamond, David	Director	-	Indirect	Purchase	14,378	0.94	$13,515.32	2,222,295	4
2023-08-31	Lamond, David	Director	-	Indirect	Purchase	41,026	1.32	$54,154.32	2,179,161	4
2023-08-17	Lamond, David	Director	-	Indirect	Purchase	24,766	1.29	$31,948.14	2,097,109	4
2023-08-10	Thye, Dirk	Director,Officer	Chief Executive Officer	Direct	Purchase	88,000	1.26	$110,880.00	448,911	4
2023-08-08	Mcloughlin, Margaret	Director	-	Direct	Purchase	8,000	1.23	$9,840.00	8,000	4
2023-08-08	Thye, Dirk	Director,Officer	Chief Executive Officer	Direct	Purchase	80,000	1.24	$99,200.00	360,911	4
2023-08-08	Hannah, Brendan	Officer	Chief Business Officer	Direct	Purchase	71,762	1.22	$87,549.64	201,555	4
2023-03-06	Monohon, Ted	Officer	Chief Accounting Officer & VP	Direct	Sale	1,871	0.98	$1,833.58	27,440	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

138.43%

Inst. Shares: 12,624,794

Shares Outstanding: 9,120,267

2025-12-31

39.89%

Inst. Shares: 19,983,163

Shares Outstanding: 50,096,897

2025-09-30

21.50%

Inst. Shares: 11,601,899

Shares Outstanding: 53,951,371

2025-06-30

16.13%

Inst. Shares: 7,530,323

Shares Outstanding: 46,686,239

2025-03-31

116.88%

Inst. Shares: 5,135,783

Shares Outstanding: 4,394,119

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	12,624,794	9,120,267	138.43%
2025-12-31	19,983,163	50,096,897	39.89%
2025-09-30	11,601,899	53,951,371	21.50%
2025-06-30	7,530,323	46,686,239	16.13%
2025-03-31	5,135,783	4,394,119	116.88%
2024-12-31	5,059,099	43,262,269	11.69%
2024-09-30	5,193,769	43,164,136	12.03%
2024-06-30	6,235,190	43,096,374	14.47%
2024-03-31	6,727,161	43,010,212	15.64%
2023-12-31	6,972,818	37,237,149	18.73%
2023-09-30	7,156,182	36,073,040	19.84%
2023-06-30	8,425,528	35,917,592	23.46%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Quince Therapeutics, Inc. (QNCX) — SEC Financial Statements & Analysis

Quince Therapeutics, Inc. (QNCX) is a biological products, (no diagnostic substances) company, incorporated in CA. Quince Therapeutics, Inc. trades on Nasdaq as: QNCX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Quince Therapeutics, Inc. reported a Debt-to-Equity ratio of -0.44x, a Price-to-Book (P/B) ratio of -3.16x (TTM), at a market cap of $111.56M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: -0.44x
P/B TTM: -3.16x
Market Cap: $111.56M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Quince Therapeutics, Inc. in?

Quince Therapeutics, Inc. (QNCX) operates in the Biological Products, (No Diagnostic Substances) industry.

What is QNCX's market cap?

Quince Therapeutics, Inc. (QNCX) has a market capitalization of $111.56M as of 2026-06-30.

What exchange does QNCX trade on?

Quince Therapeutics, Inc. (QNCX) trades on the Nasdaq.

Where is Quince Therapeutics, Inc. incorporated?

Quince Therapeutics, Inc. is incorporated in CA.